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Alzheimer diseaset pro-domain caspase that is activated early in Alzheimer disease, yet, little is
known on the mechanism of activation of this caspase. In this study, critical proteolytic processing events
required for Casp6 activation in vitro and in vivowere evaluated by site directed mutagenesis of the D23 pro-
domain, and D179 and D193 linker processing sites. We found that (1) Casp6 was self-processed and
activated in vitro and in vivo, (2) uncleavable Casp6 possessed low activity in vitro but not in vivo, (3) the pro-
domain of Casp6 entirely prevented self-processing and activation in vivo but not in vitro, (4) removal of the
pro-domain promoted Casp6 activation, (5) cleavage at either D179 or D193 was sufﬁcient to generate
activity in vitro and in vivo, and (6) Casp6 activity did not induce cell death in HEK293T cells. We conclude
that the Casp6 is activated through proteolytic cleavage, as are the effector Caspase-3 and -7. However, unlike
other effector caspases, Casp6 can be entirely self-activated and its activation does not necessarily induce cell
death.
Crown Copyright © 2008 Published by Elsevier B.V. All rights reserved.1. Introduction
Caspase (Casp) cysteinyl proteases, with speciﬁcity for Asp (D) at
their P1 position, exist as pro-enzymes in cells [1–4]. Caspases are
generally grouped according to substrate speciﬁcity or the length and
functionality of their pro-domain [5,6]. There are three short pro-
domain effector caspases, Casp3, Casp6, and Casp7, which are believed
to irreversibly commit cells to apoptosis when activated. While
intense investigations have revealed the molecular mechanisms of
Casp3 and Casp7 activation, little is known about Casp6 activation. Yet,
Casp6 is activated in the absence of Casp3 or Casp7 activation in
serum-deprived primary human neurons and Casp6 activity precedes
effector or initiator caspase activation in various cell types [7–11].
Microinjection of recombinant active Casp6, but not recombinant
active Casp3, Casp7, or Casp8, induces a protracted type of cell death in
human primary neurons, in the absence of any other insult [12]. Active
Casp6 is abundant in the neuropil threads, neuritic plaques,
neuroﬁbrillary tangles and pre-tangles of individuals with mild,
moderate, severe and very severe Alzheimer's disease (AD) [13,14].
Casp6 activity is also present in the entorhinal cortex and hippocam-
pus of individuals with mild cognitive impairment, a stage known to
often precede AD [14]. However, the Casp6 activity is not associated
with apoptotic morphology in human neurons. In primary human76; fax: +1 514 340 8295.
nc).
08 Published by Elsevier B.V. All rigneuronal protein extracts, Casp6 cleaves several important cytoske-
leton or cytoskeleton-associated proteins implicating Casp6 activity in
the modulation of neuronal cyto-architecture and function [15]. Both
Tau and alpha-Tubulin cleaved by Casp6 are detected in the
neuropathological features of AD [13–15] Furthermore, Casp6, but
not Casp3, cleavage of expanded repeat mutant huntingtin mediates
neurotoxicity and behavioral deﬁcits in a murine Huntington disease
model [16]. These investigations suggest that Casp6 plays an
important role in neurodegenerative diseases and warrant further
investigations into its mode of activation and action.
Similar to other caspases, Casp6 is transcribed as a zymogen
comprised of a short pro-domain, large subunit (p20), short linker
region and a small subunit (p10) with the catalytic cysteine located at
position 163 (position285 in Casp1numbering) of the p20 subunit. The
active form of Casp6 is a heterotetramer of two p20 and two p10
subunits generated from the zymogen by cleavage at the D23 residue
between the pro-domain and the p20 subunit and at the D179 and
D193 residues between the linker and the two subunits [17]. The active
subunits of Casp6 can be generated fromover-expression of pro-Casp6,
but not from the catalyticmutant pro-Casp6C163A, in E. coli, indicating
that Casp6 can self-activate in prokaryotic expression systems [18].
Casp6 shares some, but not all features of Casp3 and Casp7. All
three short pro-domain caspases are dimeric in solution [19–22]
although the concentration of Casp6 and Casp7 when dimers are
detected is at least 50 times that of the normal physiological
concentration [21]. While the dimer interface at residue 388hts reserved.
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Casp6 contains the bulkier Phe residue that is present in the dimer
interface of initiator caspases [23]. Phylogenetically, Casp6 is close to
Casp3 and Casp7 but is not part of the same branch [5]. While Casp3
and Casp7 share a similar substrate recognition sequence [6], the
Casp6 substrate recognition sequence is similar to that of long pro-
domain initiator Casp8 and Casp9 [6,24]. Casp6 lacks the “safety catch”
regulatory sequence present in Casp3 and Casp7 that has been shown
to prevent Casp3 self-activation [25]. Furthermore, the inhibitor of the
apoptosis family of proteins that inhibit Casp3 and Casp7 do not
inhibit Casp6 [26,27].
Very little is known about Casp6 activation and Casp6 is often
considered downstream of Casp3 activity [1,28–31]. Yet, in some cases,
Casp6 is activated prior to or in the absence of Casp3 activation
[7,10,11,32,33]. Therefore, here we investigate Casp6 processing and
activity in vitro and in vivo to determine the essential processing
events required for Casp6 activation.
2. Materials and methods
2.1. Mutagenesis and sub-cloning of the pro-Casp6 construct
The pET23b (+) recombinant Casp6-His⁎tag (kind gift from Dr. Guy
Salvesen, the Burnham Institute, La Jolla, CA) was mutated using the
QuikChange Site-directed Mutagenesis kit (Stratagene, La Jolla, CA)
according to the manufacturer's protocol with the following oligonu-
cleotides and the corresponding reverse sequence: C163A 5′ ATATT-
TATCATCCAGGCAGCTCGGGGAAACCAGCACGATGTGCC 3′; D23A 5′
CATGACAGAAACAGCTGCCTTCTATAAAAG 3′; D179A 5′ CCTTTGGATG-
TAGTAGCTAATCAGACAGAG 3′; D193A 5′ CATAACTGAGGTGGCTGC
AGCCTCCG 3′. Double and triple mutations were done with conﬁrmed
mutant constructs as template. Mutations at D23A and D193A
introduce a PvuII or a PstI restriction enzyme site, respectively. All
constructs were sent for DNA sequencing at the Sheldon Biotechnol-
ogy Centre (Montreal, Quebec) to conﬁrm the mutations. Sub-cloning
of the pro-Casp6 mutants from the pET23b(+) to the pCEP4β plasmid
were done to the KpnI and HindIII sites using the forward primer 5′
CGGGGTACCATGAGCTCGGCCTCG 3′ and reverse primer 5′
CCCAAGCTTTCAGTGGTGGTGG 3′. The pCEP4β-Casp6p20p10 was
ampliﬁed from the pET23b(+)-Casp6 construct using the forward
primer 5′ CGGGGTACCATGGCCTTCTATAAAAGAGAAATG 3′ and the
same reverse primer as above, introducing a methionine prior to
alanine 24 in the Casp6 sequence. All constructs were veriﬁed by
sequencing at the McGill University and Genome Quebec Innovation
Centre (Montreal, Quebec).
2.2. Protein expression and puriﬁcation
pET23b (+) recombinant pro-Casp6-His⁎tag (kind gift from G.
Salvesen, Burnham Institute, CA), -pET23b (+) recombinant pro-
Casp6-His⁎tag mutants, and pET21b-recombinant human pro-Casp3-
His⁎tag (pHC332) (a kind gift from Dr Clay Clark, North Carolina State
University, Raleigh, NC) were transformed in E. Coli BL21(DE3)pLysS
(Stratagene, La Jolla, CA) as described [34]. Cells were grown to
OD600=0.6 at 37 °C. Protein expression was induced with 50 µM
isopropyl-beta-D-thiogalactopyranoside (IPTG). The bacteria were
further grown overnight at 30 °C, harvested by centrifugation and
resuspended in buffer A (50 mM Tris–HCl pH 8.0, 100 mM NaCl).
Samples were sonicated on ice with a Branson S-450A soniﬁer
(Branson Ultrasonic Corporation, Danbury CT) for 2 min at 50% duty
with output control set to 6. The lysatewas centrifuged at 18000 ×g for
30 min at 4 °C, ﬁltered through a 45 µm ﬁlter, loaded on nickel-
nitrilotriacetic acid (Ni-NTA) agarose beads (QIAGEN, Mississauga,
Ontario) and washed extensively. Bound proteins were eluted with a
0–200 mM imidazole (BioShop Canada Inc, Burlington, Ontario)
continuous gradient in buffer A. Part of the fractions were evaluatedfor recombinant protein purity by Coomassie blue staining. Pure
fractions were pooled together, buffer was exchanged back to buffer A
to remove the imidazole and the proteins were concentrated on a
5000 Da molecular weight cut off Amicon Ultra centrifugal ﬁlter
(Millipore Corporation, Billerica, MA). Protein concentration was
determined by the Bradford protein assay (Pierce, Rockford, IL).
2.3. Western blots
50 ng of recombinant protein or 20 µg (HEK293T cells) of crude cell
lysatewere loaded and separated in eachwell of 15%polyacrylamide gel,
transferred to Immobilon-P polyvinylidene ﬂuoride (PVDF) membranes
and probed with the following antisera or antibodies. The neoepitope
rabbit polyclonal antiserum10630 raised against aminoacids 174–179 of
human pro-Casp6 (1:5000) and 20622 raised against amino acids 433–
438 of humanα-Tubulinwere generated in our laboratory [13,15]. Other
primary antibodies used were the anti-Casp616-32 (Mch2) rabbit
polyclonal puriﬁed IgG raised against amino acids 16–32 (1:1000)
(Upstate Cell Signaling Solutions, Charlottesville, VA), anti-Casp6 (Mch2)
Ab-4 rabbit polyclonal puriﬁed IgG (1:250) raised against theN-terminal
region of Casp6 (Neomarker, Fremont, CA), anti-human-Casp6 mouse
monoclonal IgG1 clone B93-4 (1:250) raised against amino acids 271–
285 (anti-Casp6p10) (Pharmingen, Ontario, Canada) (Fig. 1), polyclonal
anti-Casp3p17 (kind gift from D. Nicholson), and anti-β actin (1:5000)
(Sigma, clone AC-15). Immunoreactive proteins were detected with
1:5000–10000 secondary HRP-conjugated donkey anti-rabbit (GE
Healthcare/Amersham, Piscataway, NJ) or 1:5000 goat anti-mouse
(Jackson ImmunoResearch, West Grove, PA) antibodies and enhanced
chemiluminescence (GE Healthcare/Amersham, Piscataway, NJ) or
Immobilon ™Western (Millipore, Billerica, MA).
2.4. Caspase activity assays
Caspase activity was assessed by in vitro ﬂuorogenic assays using
Ac-Val-Glu-Ile-Asp-7-Amino-4-triﬂuoromethylcoumarin) (Ac-VEID-
AFC: BIOMOL International, L.P., Plymouth Meeting, PA) as the Casp6
substrate. The activity was measured every 2 min for 1 h at 37 °C in
Stennicke's buffer (20mMpiperazine-N, N-bis (2-ethanesulfonic acid)
(PIPES: BioShop Canada Inc.) pH 7.2, 30 mM NaCl, 1 mM EDTA, 0.1%
CHAPS, 10% sucrose, 10 mM DTT) [35] with or without 50 mM sodium
citrate as indicated and 90 µM Ac-VEID-AFC using a Bio-Rad Fluoro-
mark plate reader (excitation 390 nm, emission 538 nm) (Bio-Rad
Laboratories, Hercules, CA). 5 µg of BSAwas added to puriﬁed proteins
or 10 µg of protein from cell crude extract were used. Fluorescence
units were converted to the amount of moles of AFC released based on
a standard curve of 0–50 µM free AFC. Cleavage rates were calculated
from the linear phase of the assay. Statistical analysis was done in
GraphPad Prism 5.0; ANOVA test and Bonferroni post hoc tests were
performed.
2.5. Processing of Casp6 mutants by recombinant Casp3
5 µg of recombinant Casp6 mutant was incubated with or without
100 ng recombinant active Casp3 in 30 µl of Stennicke's buffer
supplemented with 10 µg BSA for 30 min at 37 °C. The mix was then
diluted 16.67 fold to 10 ng/µl of Casp6 mutant (±0.2 ng/µl Casp3) and
5 µl of the mix was tested for Casp6 activity as described above and by
Western blot with anti-Casp6p10 (Pharmingen).
2.6. Measurement of Casp6 endogenous concentrations
HEK293T cells were grown in DMEM/10% FBS and Jurkat-T cells
were grown in RPMI 1640 10% FBS. Cells were harvested and
suspended in PBS and cell volume measurements were done by Z2
Coulter® particle count and size analyzer and Z2 AccuComp® software.
Endogenous Casp6 was extracted from 5×105 cells in 50 mM Tris
Table 1
In vitro self-processing and activation of Casp6
Construct Cleaved sites Subunits generated Activity
Pro-Casp6 D23,D179,D193 Pro+p20+p10 ++++
Pro-Casp6D23A D179, D193 Pro-p20+linker+p10 ++++
Pro-Casp6D(179)A D23, D193 Pro+p20-linker+p10 ++
Pro-Casp6D(23,179)A D193 Pro-p20-linker+p10 +/−
Pro-Casp6D193A D23 Pro+p20p10 +/−
Pro-Casp6D193A +Csp3 D23, D179 Pro+p20+linker-p10 ++++
Pro-Casp6D(23,193)A – None −
Pro-Casp6D(179,193)A D23 Pro+p20p10 −
Pro-Casp6D(23,179,193)A – None +/−
Fig. 1. Uncleaved pro-Casp6 is active in vitro. (A) Schematic diagram of recombinant
Casp6, showing the subunits of Casp6 and epitopes of antibodies used. The exact
epitope for the Neomarker antiserum is unknown. Mutations generated at the
processing sites are indicated as D23A, D179A and D193A. (B) Coomassie stain or
western blot analyses of puriﬁed wild type (WT), pro-Casp6D(23,179,193)A and pro-
Casp6C163A proteins. (C) VEIDase activity of WT, D(23,179,193)A and C163A puriﬁed
recombinant Casp6 proteins in the presence of 50 mM sodium citrate. The activity of
100 nM, 300 nM, and 600 nM of Casp6D(23, 179,193)A represents 0.27%, 0.52% and
0.54% of the activity of processed WT Casp6, respectively ⁎pb0.01, ⁎⁎pb0.001 show
statistically signiﬁcant activity in WT and D(23, 179, 193)A proteins compared to the
catalytically inactive C163A Casp6 protein. (D) Endogenous concentrations of Casp6 in
HEK293T and Jurkat-T cells.
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leupeptin, 1 µg/ml TLCK, 0.1 µg/ml pepstatin A and 38 µg/ml AEBSF for
30 min on ice and triturated through a 20 gauge needle. Samples were
precipitated with methanol, separated on a 15% SDS-PAGE gel
alongside a standard curve of pro-Casp6D(23,179,193)A, and western
blotted with anti-Casp6p10 (Pharmingen). Band intensities were
measured with Gene Tool Analysis software 3.2.0.0 (SYNGENE, MD).
2.7. Transfection and protein extraction of mammalian cells
HEK293T cells were maintained in DMEM/10% FBS. 24 h before
transfection, cells were plated in 12 well plates at 300,000 cells perwell, or in 96well plates at 22,500 cells perwell in 100 µl volume. Cells
were transfected with Lipofectamine2000 (Invitrogen, Carlsbad, CA)
according to themanufacturer's protocol. Mediawas replaced 3 h after
transfection with growth media and cells were either used for
Fluorescent-activated cell sorting (FACS), CellTiter 96® Non-Radio-
active Cell Proliferation Assay (MTT assay) or harvested for protein
extractions 24 h and 48 h after transfection. For Western blots and
Casp6 activity assays, proteins were extracted with 50 mM HEPES,
0.1% CHAPS, 0.1 mM EDTA, 1 mM DTT (added fresh), 0.5 µg/ml
leupeptin, 1 µg/ml TLCK, 0.1 µg/ml pepstatin A and 38 µg/ml AEBSF
and frozen on dry ice. Protein concentration was determined by the
Bradford protein assay (Pierce, Rockford, IL). Three independent
experiments were done with all of the Casp6 constructs and controls.
2.8. Cell death evaluation
For FACS analysis, cells were harvested and washed once with cold
PBS/5 mM EDTA. Cells were then permeabilized and ﬁxed with 75%
ethanol/25% PBS/5 mM EDTA and stored at −20 °C. On the day of
analysis, cells were washed once with PBS/5 mM EDTA and then
stained with 50 µg/ml propidium iodide (Sigma, St. Louis MO), 20 µg/
ml RNase A (USB Corporation, Cleveland, OH) in PBS and analyzed for
cell cycle by FACS on a BD Calibur machine with Cell ProQuest 4.0.2
software (BD Biosciences, Franklin Lakes, NJ). For the MTT assay
(Promega, Madison, WI), the experiment was performed according to
the manufacturer's instruction and absorbance was measured at
570 nm and 650 nm.
3. Results
Since several Casp6 mutants were tested for processing and
activity in vitro and in vivo, a summary of the following results are
presented in Table 1 to facilitate the appraisal of these results.
3.1. Uncleavable pro-Casp6 exhibits VEIDase activity in vitro
To test if uncleavable pro-Casp6 has activity, we generated a triple
mutant of pro-Casp6 that eliminates the pro-domain D23 and the
linker D179 and D193 cleavage sites [pro-Casp6D(23,179,193)A] (Fig.
1A) [17] and compared it with wild-type (WT) pro-Casp6 and
catalytically inactive Pro-Casp6C163A. The recombinant proteins
were expressed in bacteria and puriﬁed for functional analyses.
Pro-Casp6 was processed into the expected p10 and p20 subunits
recognized speciﬁcally with the Pharmingen, Neomarker, or neoepi-
tope 10630 (anti-PLDVVD179) antisera, respectively (Fig. 1B). In
addition, pro-Casp6 produced a p23 subunit representing p20-linker
recognized by Neomarker but not by Upstate or 10630 antisera.
Neither the catalytic mutant pro-Casp6C163A, nor the triple mutant
pro-Casp6D(23,179,193)A, was processed. At concentrations of
≥100 nM, the uncleavable pro-Casp6D(23,179,193)A showed very
low but dose-dependent VEIDase activity compared to the wild type
(WT) pro-Casp6 whereas the catalytically inactive pro-Casp6C163A
Table 2
In vivo processing and activation of Casp6 in HEK293T cells
Construct Cleaved sites Subunits generated Activity
Pro-Casp6 D23 Pro+p20-p10 ++
Pro-Casp6D23A – None −
Pro-Casp6D23A + Serum
Deprivation
D179, D193 Pro-p20-linker+pro-p20+p10 +++
Pro-Casp6D(179)A D23 Pro+p20-p10 ++
Pro-Casp6C(163)A – None −
Pro-Casp6C(163)A + Serum
Deprivation
– None −
Pro-Casp6D(23,179,193)A – None −
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(23,179,193)A compared to that of WT Casp6 was consistent with
unprocessed Casp8, which has 1% the activity of fully processed
Casp8 [36]. The physiological concentration of pro-Casp6 in HEK293T
and Jurkat cells was 33 nM and 64 nM, respectively (Fig. 1D),
suggesting that the uncleaved Casp6 could generate activity at
physiologically relevant concentrations. Together, these results
conﬁrm pro-Casp6 self-processing and activation in vitro and suggest
that pro-Casp6 can have low activity without being proteolytically
processed.Fig. 2. Uncleaved pro-Casp6 is not active in vivo. (A) Western blots of crude protein extract
serum for 24 h. FL indicates full-length pro-Casp6, p20p10 is Casp6 lacking the pro-domain, th
of crude protein extract as in (A).3.2. Uncleavable pro-Casp6 does not exhibit activity in vivo
To examine if the expression of pro-Casp6 in vivo will result in
Casp6 activation, we expressed His-taggedWT, C163A, D(23,179,193)A
or D(23,179,193)A-C163A pro-Casp6 in HEK293T cells (Table 2). The
expression of Casp6 was easily detected from all constructs with an
anti-His antiserum 24 h after transfection (Fig. 2A). Under normal
conditions, only WT pro-Casp6 was processed and generated p20p10,
and a small amount of p20 and p23 subunits. Alpha-Tubulin cleaved by
Casp6 (α-TubΔCasp6) was detected in WT, but not in C163A, D
(23,179,193)A or D(23,179,193)A-C163A, thus further conﬁrming Casp6
activity in vivo. Furthermore, VEIDase activitywas also detected only in
protein extracts from the WT pro-Casp6 transfected cells (Fig. 2B).
To determine if pro-Casp6D(23,179,193)A may become active in
apoptotic conditions, transiently transfected HEK293T cells were
serum-deprived (Fig. 2A and B). In serum-deprived conditions, there
was a small amount of α-TubΔCasp6 detected in non-transfected,
vehicle or mock-transfected cells indicating the activation of endo-
genous Casp6. However, while increased levels of Casp6 p20/p23
subunits and α-TubΔCasp6 were detected in WT pro-Casp6 trans-
fected cells, no Casp6 activity was detected in pro-Casp6D(23,179,193)
A transfected cells (Fig. 2B). Serum deprivation did not result in
proteolysis of Casp6C163A indicating that serum deprivation does notfrom HEK293T cells transfected with indicated constructs and treated with or without
e p20 and p23 subunits are deﬁned in the result section. (B) VEIDase activity from 10 µg
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D193 processing sites of Casp6. Therefore, proteolytic processing in
pro-Casp6-transfected HEK293T cells is self-generated. Together,
these results indicate that over-expression of uncleavable pro-Casp6
does not result in Casp6 activity in vivo whereas over-expressed WT
pro-Casp6 engenders self-processing and activation.Fig. 3. Casp6 is activated by processing at either intersubunit linker sites in vitro. (A) Cooma
catalytic inactive (C163A) and singly or doubly mutated Casp6 at D23, D179 and D193. (B) VE
⁎pb0.05, ⁎⁎pb0.01 ⁎⁎⁎pb0.001 represent statistically signiﬁcant difference of VEIDase activit
mutants in the presence of 50 mM sodium citrate. ⁎pb0.01, ⁎⁎pb0.001 represent statistical
cleaved Casp6D193A with Pharmingen anti-Casp6 p10 antibody. FL—Full length, L—Linker, ⁎3.3. D193 cleavage, but not D23 or D179, is essential for Casp6
auto-processing into p10 and p20 subunits in vitro
To determine which processing sites are most important for pro-
Casp6 self-activation, we generated either single or double muta-
tions in pro-Casp6's processing sites. When expressed and puriﬁedssie stain and western blot analysis of puriﬁed recombinant wild type pro-Casp6 (WT),
IDase activity of Casp6 mutants presented as fold change relative to WT Casp6 activity.
y relative to C163A. (C) VEIDase activity of D193A and catalytically inactive C163A Casp6
ly signiﬁcant increase of VEIDase activity relative to C163A. (D) Western blot of Casp3-
pb0.001 E. VEIDase activity of Casp6D193A±active Casp3.
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p26 subunits representing the Casp6 p10 subunit, pro-p20 (p23) and
pro-p20-linker (p26), respectively (Fig. 3A). The pro-Casp6D179A
mutant generated p20p10, p10 and p20-linker (p23) subunits
indicating that processing at D179 is not relevant to processing at
D23 and D193 sites. Similarly, the double Casp6 mutant D(23,179)A
was processed at D193 and generated pro-p20-linker (p26) and p10
subunits. The pro-Casp6D193A mutant generated p20p10, but no
pro-p20 (p23), p20 or linker-p10 (p13) subunits. The double D
(23,193)A mutant was not processed while the double D(179,193)A
mutant did not prevent processing at D23. These results indicated
that D193A allowed D23, but not D179 cleavage. Consistent with the
generation of p10 and p20 subunits, the WT, D23A and D179A, but
not the D193A or any of the double mutants, displayed VEIDase
activity (Fig. 3B). The pro-p20-linker and p10 subunits generated
from the pro-Casp6D(23,179)A did not generate signiﬁcant activity.
At high concentrations, the D193A mutants possessed minimal
activity as observed with the uncleavable pro-Casp6D(23,179,193)A
indicating that the removal of the pro-domain does not enhance
VEIDase activity (Fig. 3C).
To determine if processing at the D193 was necessary for Casp6
activity or Casp6 self-activation, recombinant active Casp3 was added
to recombinant pro-Casp6D193A protein. Casp3 processed pro-
Casp6D193A at the D23 and D179 sites yielding p20p10, p20 (not
detected with the Pharmingen antibody) and linker-p10 (p13)
subunits (Fig. 3D) and reconstituted VEIDase activity (Fig. 3E).
Together, these results demonstrate that (1) signiﬁcant Casp6 activityFig. 4. Pro-Casp6 is activated by processing at D179 in vivo. (A) Western blots of crude protein
VEIDase activity from 10 µg of crude protein extract from HEK293T-transfected cells. Asteri
number sign (#) denotes signiﬁcant difference between±serum within the same construct.requires cleavage of at least one of the linker sites, and (2) the in vitro
self-processing activity of Casp6 requires cleavage at D193.
3.4. Proteolytic processing at the D179 site is essential for Casp6
self-processing and activation in mammalian cells
To assess the importance of Casp6 processing sites in mammalian
cells, HEK293T cells were transfected with WT pro-Casp6, the pro-
Casp6D23A and pro-Casp6D179A (Fig. 4A). Within 24 h of transfec-
tion, WT Casp6 was proteolytically processed at D23, D179 and D193
thereby generating p20p10 and p20/p23 subunits. Processing at these
sites was accompanied with VEIDase activity and the detection of α-
TubΔCasp6 in the protein extracts of transfected cells (Fig. 4A and B).
In contrast, pro-Casp6D179A and D23A did not generate cleaved p20
subunits or Casp6 activity. With serum deprivation, the WT and D23A
mutant generated signiﬁcant amounts of p20/p23 and p23/p26
subunits, respectively, and activity. However, the pro-Casp6D179A
mutant did not. The higher levels of Casp6 activity in D23A compared
to WT Casp6 are likely due to a higher level of D23A expression in the
transfected cells. Because the pro-Casp6C163A is not cleaved in
serum-deprived conditions and is a dominant negative inhibitor of
Casp6 activation [37], these results indicate that serum deprivation
activates endogenous Casp6, which then cleaves the Casp6D23A at the
D179 and D193 linker sites. These results show that (1) similar to in
vitro results, signiﬁcant Casp6 activity requires proteolytic processing
at the linker sites, and (2) in contrast to in vitro results, self-processing
of pro-Casp6 at D193 in vivo requires cleavage at the D179 site.extract from transfected HEK293T cells and treated with or without serum for 24 h. (B)
sk (⁎) shows statistically signiﬁcant difference compared to mock transfected cells and
⁎pb0.001, #pb0.01.
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Given that the pro-domain is removed during activation of WT
Casp6 in vitro and in vivo but that uncleaved pro-domain in the
Casp6D23A mutant also had signiﬁcant Casp6 activity in vitro, we
evaluated the inﬂuence of the pro-domain on Casp6 self-processing
and activation by comparing p20p10 to WT and D23A Casp6 (Fig. 5A).
In normal conditions, the p20p10 generated p20 and p20-linker (p23)
subunits more readily than theWT pro-Casp6 in transfected HEK293T
cells, while, as shown in Fig. 4A, the D23A mutant was not processed
(Fig. 5B). Processing was associated with Casp6 activity as determined
by the presence of α-TubΔCasp6 (Fig. 5B) and VEIDase activity (Fig.
5C). Serum deprivation did not enhance p20p10 cleavage or activity
further, but as described above, it did induce D23A processing at D179
and D193. These results indicate that the pro-domain prevents pro-
Casp6 self-activation in vivo.
3.6. Casp6 proteolytic processing results in activity but not cell death in
HEK293T cells
To determine if the activation of Casp6 induces cell death,
mitochondrial dysfunction was assessed by MTT assays in transfectedFig. 5. The pro-domain prevents Casp6 activation in vivo. (A) Schematic diagram of recombin
HEK293T cells transfected with indicated constructs and treated with or without serum for 2
cells. Asterisk (⁎) shows statistically signiﬁcant difference compared to mock transfected cel
construct. ⁎pb0.01, ⁎⁎pb0.001, #pb0.05.HEK293T cells 24 and 48 h after transfection. Not surprisingly, none of
the Casp6 mutants that were neither processed nor activated showed
MTT reduction whereas staurosporin treatment did (Fig. 6A).
Unexpectedly, WT Casp6 and the p20p10mutant, which both produce
signiﬁcant levels of active Casp6 within 24 h of serum deprivation, did
not diminish mitochondrial function. Analysis of transfected cells for
subG1 DNA content indicative of apoptotic status also did not reveal
any effect of activated Casp6 on cell death, while treatment with
staurosporin did (Fig. 6B). Furthermore, Casp3 activation was not
detected in serum-treated or serum-deprived Casp6-transfected
HEK293T cells at either 24 or 48 h of transfection (Fig. 6C). Levels of
pro-Casp3 were maintained in all transfected cells. Slightly less pro-
Casp3 in p20p10-transfected HEK293T cells at 48 h in serum
conditions was accompanied by lower levels of β-actin and thus
indicated that less protein was loaded in this lane. In contrast,
staurosporin treatment reduced the level of pro-Casp3 signiﬁcantly.
The lower levels of pro-Casp3 are not accompaniedwith an increase in
active p17 Casp3 subunit indicating that the subunit is rapidly turned
over in staurosporin-treated HEK293T cells. A faint Casp3 immunor-
eactive 23 kDa protein band occasionally was present in serum-
deprived Casp6-transfected cells but since this band was also present
in the Casp6C163A, which was not processed, it could not be
attributed to processing of Casp3 by activated Casp6. We did notant Casp6D23A and p20p10 constructs. (B) Western blots of crude protein extract from
4 h. (C) VEIDase activity from 10 µg of crude protein extract from HEK293T-transfected
ls and number sign (#) denotes signiﬁcant difference between±serum within the same
Fig. 6. Activation of Casp6 does not induce HEK293T cell death. A. MTT assay from cells
transfected with various constructs presented as a fold change relative to non-treated
control (NT). B. Percentage of transfected HEK293T cells with sub-G1 DNA content
assessed by FACS analyses. STS indicates staurosporin, ⁎pb0.001 indicates a statistically
signiﬁcant difference compared to NT cells. C. Western blot analysis of Casp3 and β-
actin in Casp6-transfected HEK293T cells.
599G. Klaiman et al. / Biochimica et Biophysica Acta 1793 (2009) 592–601treat serum-deprived cells with staurosporin because it is an efﬁcient
inducer of apoptosis and cells would be completely destroyed by 24 h
of treatment in serum-deprived conditions. These results indicate that
Casp6 activity does not activate Casp3 and does not cause apoptotic
cell death in the HEK293T cells for up to 48 h of activation.4. Discussion
In this manuscript, we found that (1) Casp6 is self-processed and
activated in vitro and in vivo, (2) uncleavable Casp6 harbors low
activity in vitro but not in vivo, (3) the pro-domain of Casp6 entirely
prevents self-processing and activation in vivo but not in vitro, (4)
removal of the pro-domain promotes Casp6 activation, (5) cleavage at
either D179 or D193 is sufﬁcient to generate Casp6 activity, and (6)
Casp6 activity does not induce cell death in HEK293T cells.
The conclusion that Casp6 can be activated by self-processing in
vitro and in vivo is based on several experimental ﬁndings. In vitro,
puriﬁcation of the C163A catalytic Casp6 mutant does not generate
processed Casp6 into its p20 and p10 subunits whereas puriﬁcation of
WT Casp6 does. Therefore, processing and activation are self-
generated as observed for Casp3 [38]. Self-activation of caspases
upon bacterial over-expression occurs through induced proximity
[39]. In vivo, expression of the WT Casp6 in HEK293T cells results in
processing at D23, D179 and D193 sites and generates Casp6 activity in
the absence of any other insult. However, expressed at similar levels,
the Casp6C163A catalytic mutant, which harbors intact processing
sites, or the Casp6D23A mutant, which has intact D179 and D193
processing sites, are not cleaved nor generate any activity in normally
treated cultures. These results indicate that upstream initiator
caspases are not responsible for the processing and activation of WT
Casp6. Self-activation of effector caspases by over-expression in
mammalian cells is not unique to Casp6. Pro-Casp7 is activated and
induces cell death in BPH cells [40]. However, the effector pro-Casp3 is
not activated by over-expression in BPH, MCF-7 or yeast cells [40–42].
We conclude that the over-expression of Casp-6 is likely sufﬁcient for
self-activation in HEK293T cells. This self-activation in vivo is
consistent with the induced proximity model [36,39] and is possibly
driven by dimerization since high concentrations of pro-Casp6 and
pro-Casp7 in vitro result in Casp6 and Casp7 dimers [21,43,44].
However, unlike the dimerization-induced activation of initiator
caspases, low levels of effector caspases in vivo would likely require
processing through initiator caspases for activation [19,36,39].
Serum deprivation of the transfected HEK293T cells increases the
amount of p20 and p10 subunits and Casp6 activity from the WT
Casp6 and induces processing of the D23A. However, the C163A
mutant was not processed in serum-deprived conditions indicating
that upstream caspases capable of processing the D23, D179 or D193
sites of Casp6 have not been activated. Since the C163A mutant is a
dominant negative Casp6, we conclude that serum deprivation-
mediated WT and Casp6D23A cleavage is due to endogenous Casp6
activation rather than from a heterogeneous caspase. Therefore, these
results support the premise that Casp6 is self-activated in vivo. The
self-activation of Casp6 in serum-deprived condition is unexpected.
Usually, an upstream protease is expected to activate effector caspases.
Casp3 is well known to be activated by apoptosomal Casp9 processing
or by initiator Casp8 [23]. Both Casp3 and Casp7 are activated in vivo
through the removal of their pro-domain by an upstream hetero-
geneous caspase [45,46]. For example, TNF-α/cycloheximide treat-
ment of Casp3C163A-transfected HeLa cells results in cleavage at the
linker site to yield the p17 subunit of Casp3 [45]. Most apoptotic
insults activate either the intrinsic or extrinsic caspase pathways that
result in Casp3 activation and Casp3 can cleave Casp6 in many
instances. However, we did not detect activation of Casp3 in serum-
deprived HEK293T cells nor the expected cell death resulting from
Casp3 activation. However, we do observe the appearance of Tubulin
cleaved by Casp6 indicating that serum deprivation has activated
Casp6. It is unlikely that other proteaseswere also prompted to activate
endogenous Casp6 since these would not have been inhibited by, and
would have processed, the Casp6C163A dominant negative. Casp6
activation is observed, in the absence of Casp3 activity, in AD tissues
except for granulovacuolar degenerating neurons [11,13,14,47–49].
Pro-Casp6 has also been reported to be over-expressed in AD [50] and
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possibility that in the absence of the activation of the Casp3 pathway,
Casp6 can be self-activated in certain conditions. The mechanism for
endogenously expressed Casp6 self-activation is not clear at this time.
Nevertheless, we can conclude that Casp6 does not behave exactly like
the other effector caspases.
Similar to uncleavable Casp3, the uncleavable pro-Casp6D
(23,179,193)A mutant possesses low activity at physiological concen-
trations in vitro [53]. This activity is only 0.5% or less of that of the
active enzyme. Nevertheless, since pro-Casp6 concentrations at which
activity is detected can be achieved in vivo via p53 transactivation, this
mechanism of self-initiation of Casp6 activity could not be entirely
excluded [51]. Furthermore, unprocessed Casp8 activity is only 1% that
of the fully processed Casp8 [36]. However, in HEK293T cells, full
length uncleavable Casp6 clearly did not generate VEIDase activity.
The lack of activation cannot be attributed to inhibition by the
inhibitor of the apoptosis family of proteins since these do not inhibit
Casp6 [26,27]. Possible explanations for the lack of in vivo activation of
the pro-Casp6D(23,179,193)A mutant are unfavorable cellular bio-
chemical conditions in HEK293T cells such as pH [53], or the presence
of interacting proteins that prevent activity [54]. Therefore, similar to
other effector caspases, it appears that signiﬁcant Casp6 activity
requires proteolytic generation of the p20 and p10 subunits.
As observed for Casp3 and Casp7 [45,46], the pro-domain of Casp6
prevents Casp6 activation since in contrast with WT Casp6, the
Casp6D23A mutant is not activated by over-expression in HEK293T
cultured in normal conditions. Furthermore, removal of the pro-
domain (Casp6p20p10) promotes its activation. Therefore, cleavage of
the pro-domain by active Casp6 as shown here, or heterogeneous
caspases will promote Casp6 activation. It is interesting to note that
the p20p10 Casp6 is as abundant as pro-Casp6 whereas Casp3p20p10
is much less abundant than pro-Casp3 in human brain or human
primary neurons protein extracts [11]. These results suggest that
Casp6 exists as a pre-activated form in human brains and thus maybe
Casp6 has a physiological function that is not only related to cell death.
In fact, while serum-deprivation-induced Casp6 activity or a direct
microinjection of active Casp6 in human primary neurons eventually
results in cell death, this occurs over a number of days [11,12],
suggesting that cell death occurs as a consequence of Casp6 activity on
other systems. The absence of cell death in HEK293T cells that clearly
show activated Casp6 for up to 48 h supports this view.
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